7 results on '"Valentinetti M"'
Search Results
2. ChemInform Abstract: Diastereoselective Addition of Methyllithium and Dimethylcuprate-Boron Trifluoride to Imines Derived from (S)-1-Phenylethylamine.
- Author
-
ALVARO, G., primary, SAVOIA, D., additional, and VALENTINETTI, M. R., additional
- Published
- 2010
- Full Text
- View/download PDF
3. ChemInform Abstract: Diastereoselective Addition of Methyllithium and Dimethylcuprate-Boron Trifluoride to Imines Derived from (S)-1-Phenylethylamine.
- Author
-
ALVARO, G., SAVOIA, D., and VALENTINETTI, M. R.
- Published
- 1997
- Full Text
- View/download PDF
4. SuperB Progress Reports -- Detector
- Author
-
M. Baszczyk, P. Dorosz, J. Kolodziej, W. Kucewicz, M. Sapor, A. Jeremie, E. Grauges Pous, G. E. Bruno, G. De Robertis, D. Diacono, G. Donvito, P. Fusco, F. Gargano, F. Giordano, F. Loddo, F. Loparco, G. P. Maggi, V. Manzari, M. N. Mazziotta, E. Nappi, A. Palano, B. Santeramo, I. Sgura, L. Silvestris, V. Spinoso, G. Eigen, J. Zalieckas, Z. Zhu, L. Jenkovszky, G. Balbi, M. Boldini, D. Bonacorsi, V. Cafaro, I. D'Antone, G. M. Dallavalle, R. Di Sipio, F. Fabbri, L. Fabbri, A. Gabrielli, D. Galli, P. Giacomelli, V. Giordano, F. M. Giorgi, C. Grandi, I. Lax, S. Lo Meo, U. Marconi, A. Montanari, G. Pellegrini, M. Piccinini, T. Rovelli, N. Semprini Cesari, G. Torromeo, N. Tosi, R. Travaglini, V. M. Vagnoni, S. Valentinetti, M. Villa, A. Zoccoli, J. F. Caron, C. Hearty, P. F. T. Lu, T. S. Mattison, J. A. McKenna, R. Y. C. So, M. Y.u. Barnyakov, V. E. Blinov, A. A. Botov, V. P. Druzhinin, V. B. Golubev, S. A. Kononov, E. A. Kravchenko, E. B. Levichev, A. P. Onuchin, S. I. Serednyakov, D. A. Shtol, Y. I. Skovpen, E. P. Solodov, A. Cardini, M. Carpinelli, D. S. T. Chao, C. H. Cheng, D. A. Doll, B. Echenard, K. Flood, J. Hanson, D. G. Hitlin, P. Ongmongkolkul, F. C. Porter, R. Y. Zhu, N. Randazzo, E. De La Cruz Burelo, Y. Zheng, P. Campos, M. De Silva, A. Kathirgamaraju, B. Meadows, B. Pushpawela, Y. Shi, M. Sokoloff, G. Lopez Castro, V. Ciaschini, P. Franchini, F. Giacomini, A. Paolini, G. A. Calderon Polania, S. Laczek, P. Romanowicz, B. Szybinski, M. Czuchry, L. Flis, D. Harezlak, J. Kocot, M. Radecki, M. Sterzel, T. Szepieniec, T. Szymocha, P. Wójcik, M. Andreotti, W. Baldini, R. Calabrese, V. Carassiti, G. Cibinetto, A. Cotta Ramusino, F. Evangelisti, A. Gianoli, E. Luppi, R. Malaguti, M. Manzali, M. Melchiorri, M. Munerato, C. Padoan, V. Santoro, L. Tomassetti, M. M. Beretta, M. Biagini, M. Boscolo, E. Capitolo, R. de Sangro, M. Esposito, G. Felici, G. Finocchiaro, M. Gatta, C. Gatti, S. Guiducci, S. Lauciani, P. Patteri, I. Peruzzi, M. Piccolo, P. Raimondi, M. Rama, C. Sanelli, S. Tomassini, P. Fabbricatore, D. Delepine, M. A. Reyes Santos, M. Chrzaszcz, R. Grzymkowski, P. Knap, J. Kotula, T. Lesiak, J. Ludwin, J. Michalowski, B. Pawlik, B. Rachwal, M. Stodulski, J. Wiechczynski, M. Witek, L. Zawiejski, M. Zdybal, V. Y. Aushev, A. Ustynov, N. Arnaud, P. Bambade, C. Beigbeder, F. Bogard, M. Borsato, D. Breton, J. Brossard, L. Burmistrov, D. Charlet, V. Chaumat, O. Dadoun, M. El Berni, J. Maalmi, V. Puill, C. Rimbault, A. Stocchi, V. Tocut, A. Variola, S. Wallon, G. Wormser, F. Grancagnolo, E. Ben Haim, S. Sitt, M. Baylac, O. Bourrion, J. M. Deconto, Y. Gomez Martinez, N. Monseu, J. F. Muraz, J. S. Real, C. Vescovi, R. Cenci, A. Jawahery, D. Roberts, E. W. Twedt, R. Cheaib, D. Lindemann, S. Nderitu, P. Patel, S. H. Robertson, D. Swersky, A. Warburton, E. Cuautle Flores, G. Toledo Sanchez, P. Biassoni, L. Bombelli, M. Citterio, S. Coelli, C. Fiorini, V. Liberali, M. Monti, B. Nasri, N. Neri, F. Palombo, F. Sabatini, A. Stabile, A. Berra, A. Giachero, C. Gotti, D. Lietti, M. Maino, G. Pessina, M. Prest, J. P. Martin, M. Simard, N. Starinski, P. Taras, A. Drutskoy, S. Makarychev, A. V. Nefediev, A. Aloisio, G. De Nard, DELLA PIETRA, MASSIMO, A. Doria, GIORDANO, RAFFAELE, A. Ordine, S. Pardi, RUSSO, GUIDO, C. Sciacca, I. I. Bigi, C. P. Jessop, W. Wang, M. Bellato, M. Benettoni, M. Corvo, A. Crescente, F. Dal Corso, U. Dosselli, C. Fanin, A. Gianelle, S. Longo, M. Michelotto, F. Montecassiano, M. Morandin, R. Pengo, M. Posocco, M. Rotondo, G. Simi, R. Stroili, L. Gaioni, A. Manazza, M. Manghisoni, L. Ratti, V. Re, G. Traversi, S. Zucca, S. Bizzaglia, M. Bizzarri, C. Cecchi, S. Germani, M. Lebeau, P. Lubrano, E. Manoni, A. Papi, A. Rossi, G. Scolieri, G. Batignani, S. Bettarini, G. Casarosa, A. Cervelli, A. Fella, F. Forti, M. Giorgi, L. Lilli, A. Lusiani, B. Oberhof, A. Paladino, F. Pantaleo, E. Paoloni, A. L. Perez Perez, G. Rizzo, J. Walsh, A. Fernández Téllez, G. Beck, M. Berman, A. Bevan, F. Gannaway, G. Inguglia, A. J. Martin, J. Morris, V. Bocci, M. Capodiferro, G. Chiodi, I. Dafinei, N. V. Drenska, R. Faccini, F. Ferroni, C. Gargiulo, P. Gauzzi, C. Luci, R. Lunadei, G. Martellotti, F. Pellegrino, V. Pettinacci, D. Pinci, L. Recchia, D. Ruggeri, A. Zullo, P. Camarri, R. Cardarelli, C. De Santis, A. Di Ciaccio, V. Di Felice, F. Di Palma, A. Di Simone, L. Marcelli, R. Messi, D. Moricciani, R. Sparvoli, S. Tammaro, P. Branchini, A. Budano, S. Bussino, M. Ciuchini, F. Nguyen, A. Passeri, F. Ruggieri, E. Spiriti, F. Wilson, I. Leon Monzon, J. R. Millan Almaraz, P. L. M. Podesta Lerma, D. Aston, B. Dey, A. Fisher, P. D. Jackson, D. W. G. S. Leith, S. Luitz, D. MacFarlane, M. McCulloch, S. Metcalfe, A. Novokhatski, S. Osier, R. Prepost, B. Ratcliff, J. Seeman, M. Sullivan, J. Va'vra, U. Wienands, W. Wisniewski, B. D. Altschul, M. V. Purohit, J. Baudot, I. Ripp Baudot, G. A. P. Cirrone, G. Cuttone, O. Bezshyyko, G. Dolinska, A. Soffer, F. Bianchi, F. De Mori, A. Filippi, D. Gamba, S. Marcello, M. Bomben, L. Bosisio, P. Cristaudo, L. Lanceri, B. Liberti, I. Rashevskaya, C. Stella, E. S. Vallazza, L. Vitale, G. Auriemma, C. Satriano, F. Martinez Vidal, J. Mazorra de Cos, A. Oyanguren, P. Ruiz Valls, A. Beaulieu, S. Dejong, J. Franta, M. J. Lewczuk, M. Roney, R. Sobie, CAVALIERE, SERGIO, M. Baszczyk , P. Dorosz, J. Kolodziej, W. Kucewicz, M. Sapor, A. Jeremie, E. Grauges Pous, G.E. Bruno, G. De Robertis, D. Diacono, G. Donvito, P. Fusco, F. Gargano, F. Giordano, F. Loddo, F. Loparco, G.P. Maggi, V. Manzari, M.N. Mazziotta, E. Nappi, A. Palano, B. Santeramo, I. Sgura, L. Silvestris, V. Spinoso, G. Eigen, J. Zalieckas, Z. Zhu, L. Jenkovszky, G. Balbi, M. Boldini, D. Bonacorsi, V. Cafaro, I. D'Antone, G.M. Dallavalle , R. Di Sipio, F. Fabbri, L. Fabbri, A. Gabrielli, D. Galli , P. Giacomelli, V. Giordano, F.M. Giorgi, C. Grandi, I. Lax , S. Lo Meo , U. Marconi, A. Montanari, G. Pellegrini , M. Piccinini, T. Rovelli, N. Semprini Cesari , G. Torromeo , N. Tosi , R. Travaglini, V.M. Vagnoni , S. Valentinetti, M. Villa, A. Zoccoli , J. -F. Caron , C. Hearty, P. F. -T. Lu, T.S. Mattison, J.A. McKenna, R. Y. -C. So , M. Yu. Barnyakov, V.E. Blinov, A.A. Botov, V.P. Druzhinin, V.B. Golubev, S.A. Kononov, E.A. Kravchenko, E.B. Levichev, A.P. Onuchin, S.I. Serednyakov, D.A. Shtol, M., Baszczyk, P., Dorosz, J., Kolodziej, W., Kucewicz, M., Sapor, A., Jeremie, E., Grauges Pou, G. E., Bruno, G., De Roberti, D., Diacono, G., Donvito, P., Fusco, F., Gargano, F., Giordano, F., Loddo, F., Loparco, G. P., Maggi, V., Manzari, M. N., Mazziotta, E., Nappi, A., Palano, B., Santeramo, I., Sgura, L., Silvestri, V., Spinoso, G., Eigen, J., Zaliecka, Z., Zhu, L., Jenkovszky, G., Balbi, M., Boldini, D., Bonacorsi, V., Cafaro, I., D'Antone, G. M., Dallavalle, R., Di Sipio, F., Fabbri, L., Fabbri, A., Gabrielli, D., Galli, P., Giacomelli, V., Giordano, F. M., Giorgi, C., Grandi, I., Lax, S., Lo Meo, U., Marconi, A., Montanari, G., Pellegrini, M., Piccinini, T., Rovelli, N., Semprini Cesari, G., Torromeo, N., Tosi, R., Travaglini, V. M., Vagnoni, S., Valentinetti, M., Villa, A., Zoccoli, J. F., Caron, C., Hearty, P. F. T., Lu, T. S., Mattison, J. A., Mckenna, R. Y. C., So, Barnyakov, M. Y. u., V. E., Blinov, A. A., Botov, V. P., Druzhinin, V. B., Golubev, S. A., Kononov, E. A., Kravchenko, E. B., Levichev, A. P., Onuchin, S. I., Serednyakov, D. A., Shtol, Y. I., Skovpen, E. P., Solodov, A., Cardini, M., Carpinelli, D. S. T., Chao, C. H., Cheng, D. A., Doll, B., Echenard, K., Flood, J., Hanson, D. G., Hitlin, P., Ongmongkolkul, F. C., Porter, R. Y., Zhu, N., Randazzo, E., De La Cruz Burelo, Y., Zheng, P., Campo, M., De Silva, A., Kathirgamaraju, B., Meadow, B., Pushpawela, Y., Shi, M., Sokoloff, G., Lopez Castro, V., Ciaschini, P., Franchini, F., Giacomini, A., Paolini, G. A., Calderon Polania, S., Laczek, P., Romanowicz, B., Szybinski, M., Czuchry, L., Fli, D., Harezlak, J., Kocot, M., Radecki, M., Sterzel, T., Szepieniec, T., Szymocha, P., Wójcik, M., Andreotti, W., Baldini, R., Calabrese, V., Carassiti, G., Cibinetto, A., Cotta Ramusino, F., Evangelisti, A., Gianoli, E., Luppi, R., Malaguti, M., Manzali, M., Melchiorri, M., Munerato, C., Padoan, V., Santoro, L., Tomassetti, M. M., Beretta, M., Biagini, M., Boscolo, E., Capitolo, R., de Sangro, M., Esposito, G., Felici, G., Finocchiaro, M., Gatta, C., Gatti, S., Guiducci, S., Lauciani, P., Patteri, I., Peruzzi, M., Piccolo, P., Raimondi, M., Rama, C., Sanelli, S., Tomassini, P., Fabbricatore, D., Delepine, M. A., Reyes Santo, M., Chrzaszcz, R., Grzymkowski, P., Knap, J., Kotula, T., Lesiak, J., Ludwin, J., Michalowski, B., Pawlik, B., Rachwal, M., Stodulski, J., Wiechczynski, M., Witek, L., Zawiejski, M., Zdybal, V. Y., Aushev, A., Ustynov, N., Arnaud, P., Bambade, C., Beigbeder, F., Bogard, M., Borsato, D., Breton, J., Brossard, L., Burmistrov, D., Charlet, V., Chaumat, O., Dadoun, M., El Berni, J., Maalmi, V., Puill, C., Rimbault, A., Stocchi, V., Tocut, A., Variola, S., Wallon, G., Wormser, F., Grancagnolo, E., Ben Haim, S., Sitt, M., Baylac, O., Bourrion, J. M., Deconto, Y., Gomez Martinez, N., Monseu, J. F., Muraz, J. S., Real, C., Vescovi, R., Cenci, A., Jawahery, D., Robert, E. W., Twedt, R., Cheaib, D., Lindemann, S., Nderitu, P., Patel, S. H., Robertson, D., Swersky, A., Warburton, E., Cuautle Flore, G., Toledo Sanchez, P., Biassoni, L., Bombelli, M., Citterio, S., Coelli, C., Fiorini, V., Liberali, M., Monti, B., Nasri, N., Neri, F., Palombo, F., Sabatini, A., Stabile, A., Berra, A., Giachero, C., Gotti, D., Lietti, M., Maino, G., Pessina, M., Prest, J. P., Martin, M., Simard, N., Starinski, P., Tara, A., Drutskoy, S., Makarychev, A. V., Nefediev, A., Aloisio, Cavaliere, Sergio, G., De Nard, DELLA PIETRA, Massimo, A., Doria, Giordano, Raffaele, A., Ordine, S., Pardi, Russo, Guido, C., Sciacca, I. I., Bigi, C. P., Jessop, W., Wang, M., Bellato, M., Benettoni, M., Corvo, A., Crescente, F., Dal Corso, U., Dosselli, C., Fanin, A., Gianelle, S., Longo, M., Michelotto, F., Montecassiano, M., Morandin, R., Pengo, M., Posocco, M., Rotondo, G., Simi, R., Stroili, L., Gaioni, A., Manazza, M., Manghisoni, L., Ratti, V., Re, G., Traversi, S., Zucca, S., Bizzaglia, M., Bizzarri, C., Cecchi, S., Germani, M., Lebeau, P., Lubrano, E., Manoni, A., Papi, A., Rossi, G., Scolieri, G., Batignani, S., Bettarini, G., Casarosa, A., Cervelli, A., Fella, F., Forti, M., Giorgi, L., Lilli, A., Lusiani, B., Oberhof, A., Paladino, F., Pantaleo, E., Paoloni, A. L., Perez Perez, G., Rizzo, J., Walsh, A., Fernández Téllez, G., Beck, M., Berman, A., Bevan, F., Gannaway, G., Inguglia, A. J., Martin, J., Morri, V., Bocci, M., Capodiferro, G., Chiodi, I., Dafinei, N. V., Drenska, R., Faccini, F., Ferroni, C., Gargiulo, P., Gauzzi, C., Luci, R., Lunadei, G., Martellotti, F., Pellegrino, V., Pettinacci, D., Pinci, L., Recchia, D., Ruggeri, A., Zullo, P., Camarri, R., Cardarelli, C., De Santi, A., Di Ciaccio, V., Di Felice, F., Di Palma, A., Di Simone, L., Marcelli, R., Messi, D., Moricciani, R., Sparvoli, S., Tammaro, P., Branchini, A., Budano, S., Bussino, M., Ciuchini, F., Nguyen, A., Passeri, F., Ruggieri, E., Spiriti, F., Wilson, I., Leon Monzon, J. R., Millan Almaraz, P. L. M., Podesta Lerma, D., Aston, B., Dey, A., Fisher, P. D., Jackson, D. W. G. S., Leith, S., Luitz, D., Macfarlane, M., Mcculloch, S., Metcalfe, A., Novokhatski, S., Osier, R., Prepost, B., Ratcliff, J., Seeman, M., Sullivan, J., Va'Vra, U., Wienand, W., Wisniewski, B. D., Altschul, M. V., Purohit, J., Baudot, I., Ripp Baudot, G. A. P., Cirrone, G., Cuttone, O., Bezshyyko, G., Dolinska, A., Soffer, F., Bianchi, F., De Mori, A., Filippi, D., Gamba, S., Marcello, M., Bomben, L., Bosisio, P., Cristaudo, L., Lanceri, B., Liberti, I., Rashevskaya, C., Stella, E. S., Vallazza, L., Vitale, G., Auriemma, C., Satriano, F., Martinez Vidal, J., Mazorra de Co, A., Oyanguren, P., Ruiz Vall, A., Beaulieu, S., Dejong, J., Franta, M. J., Lewczuk, M., Roney, R., Sobie, Universitat Autònoma de Barcelona (UAB), Laboratoire de l'Accélérateur Linéaire (LAL), Université Paris-Sud - Paris 11 (UP11)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Laboratori Nazionali di Frascati (LNF), Istituto Nazionale di Fisica Nucleare (INFN), Laboratoire de Physique Nucléaire et de Hautes Énergies (LPNHE), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), SLAC National Accelerator Laboratory (SLAC), Stanford University, SuperB, and Starita, Sabine
- Subjects
[PHYS.HEXP] Physics [physics]/High Energy Physics - Experiment [hep-ex] ,[PHYS.PHYS.PHYS-INS-DET] Physics [physics]/Physics [physics]/Instrumentation and Detectors [physics.ins-det] ,[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex] ,[PHYS.PHYS.PHYS-INS-DET]Physics [physics]/Physics [physics]/Instrumentation and Detectors [physics.ins-det] - Abstract
95 pages, 48 pdf figures; This report describes the present status of the detector design for SuperB. It is one of four separate progress reports that, taken collectively, describe progress made on the SuperB Project since the publication of the SuperB Conceptual Design Report in 2007 and the Proceedings of SuperB Workshop VI in Valencia in 2008. The other three reports relate to Physics, Accelerator and Computing.
- Published
- 2010
5. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.
- Author
-
Romaguera JE, Wang M, Feng L, Fayad LE, Hagemeister F, McLaughlin P, Rodriguez MA, Fanale M, Orlowski R, Kwak LW, Neelapu S, Oki Y, Pro B, Younes A, Samaniego F, Fowler N, Hartig K, Valentinetti M, Smith J, Ford P, Naig A, Medeiros LJ, Kantarjian HM, and Goy A
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Bortezomib administration & dosage, Bortezomib adverse effects, Chemotherapy-Induced Febrile Neutropenia etiology, Cyclophosphamide administration & dosage, Cyclophosphamide adverse effects, Cytarabine administration & dosage, Cytarabine adverse effects, Dexamethasone administration & dosage, Dexamethasone adverse effects, Dose-Response Relationship, Drug, Doxorubicin administration & dosage, Doxorubicin adverse effects, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Incidence, Kaplan-Meier Estimate, Lymphoma, Mantle-Cell mortality, Male, Methotrexate administration & dosage, Methotrexate adverse effects, Middle Aged, Neoplasm Recurrence, Local prevention & control, Prospective Studies, Rituximab administration & dosage, Rituximab adverse effects, Survival Rate, Time Factors, Treatment Failure, Vincristine administration & dosage, Vincristine adverse effects, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Chemotherapy-Induced Febrile Neutropenia epidemiology, Lymphoma, Mantle-Cell drug therapy, Neoplasm Recurrence, Local epidemiology
- Abstract
Background: Although the outcomes of patients with mantle cell lymphoma (MCL) have improved, there is still no cure. Bortezomib has a 33% response rate in relapsed/refractory MCL and has shown additive and/or synergistic effects in preclinical trials with known effective agents., Methods: This is a report of a prospective phase 2 trial of bortezomib added to rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (BzR-hyperCVAD)/rituximab, high-dose methotrexate, and high-dose cytarabine (BzR-MA) for 95 patients with newly diagnosed MCL., Results: The overall and complete response rates were 100% and 82%, respectively. Hematologic toxicity was high but expected and did not lead to an increased incidence of neutropenic fever or dose reductions in comparison with a similar reported regimen without bortezomib. After a median follow-up of 44 months, the median overall survival had not been reached, and the time to treatment failure (TTF) was 55 months, which is not different from that of historical controls., Conclusions: BzR-hyperCVAD/BzR-MA at the dose and schedule studied produced high rates of response and a TTF similar to that of historical reports without bortezomib. Cancer 2018;124:2561-9. © 2018 American Cancer Society., (© 2018 American Cancer Society.)
- Published
- 2018
- Full Text
- View/download PDF
6. Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.
- Author
-
Mato AR, Foon KA, Feldman T, Schuster SJ, Svoboda J, Chow KF, Valentinetti M, Mrkulic M, Azzollini K, Gadaleta G, Bhattacharyya PK, Zenreich J, Pascual LN, Yannotti K, Kdiry S, Howlett C, Strelec L, Porter D, Bejot C, and Goy A
- Subjects
- Adult, Aged, Antibodies, Monoclonal, Murine-Derived administration & dosage, Antibodies, Monoclonal, Murine-Derived adverse effects, Antineoplastic Combined Chemotherapy Protocols adverse effects, Cyclophosphamide administration & dosage, Cyclophosphamide adverse effects, Disease-Free Survival, Female, Humans, Lenalidomide, Leukemia, Lymphocytic, Chronic, B-Cell mortality, Male, Middle Aged, Remission Induction, Rituximab, Survival Rate, Thalidomide administration & dosage, Thalidomide adverse effects, Thalidomide analogs & derivatives, Vidarabine administration & dosage, Vidarabine adverse effects, Vidarabine analogs & derivatives, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy
- Abstract
Fludarabine, cyclophosphamide, and rituximab (FCR) remains the standard of care for fit chronic lymphocytic leukemia (CLL) patients requiring first therapy. However, side effects can be significant, and patients with poor risk features have inferior outcomes. The purpose of this study was to evaluate reduced-dose FCR (FCR-Lite) plus lenalidomide (FCR(2) ) followed by lenalidomide maintenance as a strategy to shorten immunochemotherapy in untreated CLL. Patients received four to six cycles of FCR(2) . Patients who were minimal residual disease (MRD) negative in peripheral blood (PB) and bone marrow (BM) initiated 12 months of lenalidomide maintenance after either four or six cycles (based on MRD status). The primary study endpoint was the complete response (CR) rate after four cycles of FCR(2) . Twenty patients were evaluable. After four cycles of FCR(2) , response rates were: CR, 45.0%; CR with incomplete blood count recovery (CRi), 5.0%; partial response (PR), 45.0%; and stable disease (SD), 5.0%. BM and PB samples from 27.8% and 52.9% of patients, respectively, were MRD negative. After six cycles, response rates were: CR, 58.3%; CRi, 16.7%; and PR, 25.0%. BM and PB samples from 50.0% and 72.7% of patients, respectively, were MRD negative. Overall, 75% of evaluable patients achieved a CR or CRi following FCR(2) . After 17.4 months of median follow-up, one progression and one death occurred. Our findings suggest that FCR(2) combines encouraging clinical activity with acceptable toxicity in previously untreated CLL. Lenalidomide can be safely added to FCR and may reduce chemotherapy exposure without compromising outcomes., (© 2015 Wiley Periodicals, Inc.)
- Published
- 2015
- Full Text
- View/download PDF
7. Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma.
- Author
-
Feldman T, Mato AR, Chow KF, Protomastro EA, Yannotti KM, Bhattacharyya P, Yang X, Donato ML, Rowley SD, Carini C, Valentinetti M, Smith J, Gadaleta G, Bejot C, Stives S, Timberg M, Kdiry S, Pecora AL, Beaven AW, and Goy A
- Subjects
- Adult, Aged, Antibodies, Monoclonal, Murine-Derived administration & dosage, Antibodies, Monoclonal, Murine-Derived adverse effects, Antineoplastic Combined Chemotherapy Protocols adverse effects, Bone Marrow Transplantation, Carboplatin administration & dosage, Carboplatin adverse effects, Dose-Response Relationship, Drug, Etoposide administration & dosage, Etoposide adverse effects, Female, Humans, Ifosfamide administration & dosage, Ifosfamide adverse effects, Lenalidomide, Lymphoma, Large B-Cell, Diffuse pathology, Male, Middle Aged, Neoplasm Staging, Prognosis, Recurrence, Rituximab, Salvage Therapy adverse effects, Salvage Therapy methods, Thalidomide administration & dosage, Thalidomide adverse effects, Thalidomide analogs & derivatives, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Lymphoma, Large B-Cell, Diffuse drug therapy
- Abstract
Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) is associated with a poor prognosis. Outcomes are particularly poor following immunochemotherapy failure or relapse within 12 months of induction. We conducted a Phase I/II trial of lenalidomide plus RICE (rituximab, ifosfamide, carboplatin, and etoposide) (RICER) as a salvage regimen for first-relapse or primary refractory DLBCL. Dose-escalated lenalidomide was combined with RICE every 14 d. After three cycles of RICER, patients with chemosensitive disease underwent stem cell collection and consolidation with BEAM [BCNU (carmustine), etoposide, cytarabine, melphalan] followed by autologous stem cell transplantation (autoSCT). Patients who recovered from autoSCT toxicities within 90 d initiated maintenance treatment with lenalidomide 25 mg daily for 21 d every 28 d for 12 months. No dose-limiting or unexpected toxicities occurred with lenalidomide 25 mg plus RICE. Grade 3/4 haematological toxicities resolved appropriately, and planned dose density and dose intensity of RICER were preserved. No lenalidomide or RICE dose reductions were required in any of the three cycles. After two cycles of RICER, nine of 15 patients (60%) achieved a complete response, and two achieved a partial response (13%). Combining lenalidomide with RICE is feasible, and results in promising response rates (particularly complete response rates) in high-risk DLBCL patients., (© 2014 The Authors. British Journal of Haematology published by John Wiley & Sons Ltd.)
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.